(Q36492418)

14 August 2017

1 reference

title

Polyomavirus-associated nephropathy: update on antiviral strategies (English)

1 reference

polyomavirus-associated nephropathy

14 August 2017

main subject

1 reference

M A Josephson

1

1 reference

14 August 2017

J W Williams

series ordinal

2

1 reference

14 August 2017

A Chandraker

series ordinal

3

1 reference

14 August 2017

P S Randhawa

series ordinal

4

1 reference

14 August 2017

publication date

1 June 2006

1 reference

Transplant Infectious Disease

14 August 2017

published in

1 reference

14 August 2017

volume

8

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

95-101

1 reference

Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Experiences with leflunomide in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Leflunomide therapy for cytomegalovirus disease in renal allograft recepients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Leflunomide for polyomavirus type BK nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Treatment of renal allograft polyoma BK virus infection with leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Fluoroquinolones: structure and target sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Antiviral activity of gyrase inhibitors norfloxacin, coumermycin A1 and nalidixic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Altered DNA binding and replication activities of JC Virus T-antigen mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

SV40 large T antigen functions in DNA replication and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Transactivation of BKV and SV40 early promoters by BKV and SV40 T-antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3062.2006.00150.X

10.1111/J.1399-3062.2006.00150.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference